Breast Cancer Clinical Trial
Official title:
Stage IV Breast Cancer Gene Expression Control Using Micro-Trace and Plant Extracted Natural G.R.A.S. (Generally Accepted As Safe), Compounds in Adjunct Therapy Alongside Conventional Cancer Protocols
Verified date | January 2020 |
Source | Brabant Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
RATIONALE: Plant extracted natural compounds, in an adjunct therapy position, slow the growth
and reproduction of Stage IV Breast Cancer tumor cells. May help eradicate different types of
cancers.
PURPOSE: The purpose of this randomized Phase I trial is to first IDENTIFY, through
laboratory analysis and validating cellular biochemical pathways, and HELP CONTROL, using
natural plant extracted compounds, G.R.A.S. (Generally Accepted As Safe), compounds, the
reproduction, growth progress and metastasis of Stage IV Breast Cancer cells. The therapy
position is adjunct to conventional therapies and in "one-off" trials have been excitingly
effective for long-term survival. Novel use of bioactive GRAS compounds to augment and
enhance conventional cancer therapies and as stand-alone parallel therapies.
Status | Not yet recruiting |
Enrollment | 300 |
Est. completion date | September 2021 |
Est. primary completion date | March 2021 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Diagnosis of prostate, breast, or uterine cancer - Early or late stage disease - Currently waiting to initiate conventional therapy or radiotherapy OR receiving concurrent conventional chemotherapy or radiation therapy - Hormone receptor status not specified PATIENT CHARACTERISTICS: - Menopausal status not specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Prior or concurrent chemotherapy or hormonal therapy for cancer allowed |
Country | Name | City | State |
---|---|---|---|
United States | Brabant Research, Incorporated | Spokane Valley | Washington |
Lead Sponsor | Collaborator |
---|---|
Brabant Research |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Utilize GRAS plant extracted compounds for suppression of cancer-cell replication. | Using adjunct therapy to augment and increase efficacy of conventional cancer treatments | 12 months | |
Primary | Suppression of cancer genetic pathways to reproduction. | suppress cancer cell proliferation | 6 months | |
Primary | Reduction of secondary bonding of TMPRSS2-ERG fusing using, among other modes of action, DPPH radical-scavenging activity | Monitor levels | 6 months | |
Primary | Monitor normal metabolic function while measuring cancer-marker levels. | metabolic function testing | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |